AC Immune ACIU 深 沪
等待开盘 10-09 09:30:00 美东时间
2.55
-0.020
-0.78%
华盛通- 最 高2.61
- 今 开2.57
- 成交量 23.19万股
- 最 低 2.50
- 昨 收 2.57
- 总市值 2.54亿
- 52周最高 4.00
- 市盈率 静 --
- 换手率 0.23%
- 52周最低 2.095
- 委 比 -71.18%
- 总股本 9942.69万
- 历史最高 17.40
- 量 比 0.89
- 振 幅 4.28%
- 历史最低 1.4299
- 每 手 1
- 风险率 0.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AC Immune Posts Strong Week-100 Phase 2 Data for Parkinson’s Vaccine ACI-7104
AC Immune SA ( ($ACIU) ) has shared an announcement. On September 23, 2026, AC ...
09-23 19:28
AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104
AC Immune announced positive results from Part 1 of the VacSYn Phase 2 trial of ACI-7104 in early-stage Parkinson’s disease, meeting all primary endpoints of safety, tolerability, and immunogenicity. ACI-7104 was shown to be generally safe and well-tolerated, with 100% of patients developing antibodies against the a-syn target antigen after three immunizations. Robust antibody penetration into the cerebrospinal fluid (CSF) was observed, along wit...
09-23 11:00
美股大行评级 | 塔吉特获13家大行上调目标价；Moderna携手默沙东齐获大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx Pharmaceutical"超配"评级，目标价从96美元升至103美元；Canaccord Genuity：维持Ultragenyx Pharmaceutical"买入"评级，目标价从81美元升至83美元
08-21 11:40
AC Immune Says Early Data from Anti-Inflammatory Drug Gives Wider Clinical Momentum for Pipeline
AC Immune SA (NASDAQ:ACIU) reported favorable interim Phase 1 clinical trial results for ACI-19764, an orally administered drug designed to target the NLRP3 inflammasome. The clinical-stage biopharmaceutical company primarily focuses on developing targeted therapies for neurodegenerative conditions....
08-21 00:32
BTIG Reiterates Buy on AC Immune, Maintains $8 Price Target
BTIG analyst Thomas Shrader reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $8 price target.
08-20 22:30
AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764
AC Immune announced positive interim Phase 1 data for ACI-19764, an oral NLRP3 inflammasome inhibitor. The drug demonstrated safety, tolerability, and brain penetration in healthy volunteers, with doses ≤10mg showing therapeutic potential. Initial anti-inflammatory activity testing in a cardiovascular risk cohort is underway, with results expected by year-end. Full Phase 1/1b results are anticipated in H1 2027. AC Immune aims to advance ACI-19764...
08-20 11:00
AC Immune reports 1H results
AC Immune press release (ACIU): 1H total revenues for the six months ended June 30, 2026 were CHF16.2 million compared with CHF2.3 million for the same period in 2025. The increase was due to the achi...
08-05 19:44
AC Immune First Half 2026 Financial and Corporate Update
AC Immune provided an update on its H1 2026 financial and corporate progress, highlighting advancements in its pipeline and partnered programs. The company’s wholly-owned programs, including ACI-7104 for Parkinson’s disease and ACI-19764 for neurodegenerative disorders, are nearing clinical milestones. Partnered programs, such as the ABATE trial with Takeda and Morphomer-Tau with Lilly, have generated milestone payments totaling $12 million. AC I...
08-05 11:00
阿尔茨海默病概念股日内下跌 AC Immune跌8.94% 礼来跌2.62% 渤健跌1.37%
阿尔茨海默病概念股在盘中交易中走低，相关个股跌幅如下： AC免疫公司下跌8.94% 礼来公司下跌2.62% 渤健公司下滑1.37% 译文内容由第三方软件翻译...
06-30 22:46
AC Immune Announces Interim 12-Month Data From Its Phase 1b/2 ABATE Trial Of ACI-24 In Prodromal Alzheimer’s Disease; ACI-24 Generally Safe And Well Tolerated in First Three Cohorts
AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced interim data from the first three cohorts (AD1, AD2 & AD3) of 74 patients with prodromal Alzheimer’s disease (AD) in the Phase 1b/2 ABATE trial fol...
06-30 19:14
